EQPT enters its first earnings call as a public company with a striking contradiction: the stock has surged 27% in a week, yet short sellers have been building positions at the fastest pace since its IPO.
Short interest has become the defining tension in this stock. It climbed from 8.9% of the free float on May 1 to 11.1% by May 12 — a jump of roughly 24% in under two weeks, and up 39% over the past month. In raw terms, nearly 12.4 million shares are currently sold short. That is a meaningful and growing bet against a newly listed company, one that the official FINRA fortnightly settlement data corroborates, with days-to-cover running at 6.3. The question is whether this reflects genuine fundamental scepticism or a hedge against the post-IPO lock-up and pricing uncertainty that typically surrounds new listings.
The borrow market adds texture to that story. Cost to borrow has nearly doubled over the past week, climbing from around 1.1% to 2.2% — still inexpensive in absolute terms, but the rate of change is notable. Availability of shares to borrow runs at 78% of short interest, meaning supply is tighter than a normal-range stock but not yet constrained enough to threaten a technical squeeze. The one significant inflection was on May 7 and 8, when the utilisation of available lending inventory briefly touched 97–98% — nearly every share in the lending pool was out on loan. That eased sharply after the weekend to 62%, which coincides with the sharp rise in short-shares figures over the same period, suggesting new borrow inventory was unlocked to meet demand. Options positioning, by contrast, tells a calmer story: the put/call ratio has dropped to 0.64 from a high of 1.72 earlier this week, now essentially in line with its 20-day average. After a period of hedging demand at the start of the week, options traders appear to have shifted toward a more neutral stance going into the earnings print.
The Street is constructive but has been trimming targets. Five analysts carry buy or outperform ratings with no sells. Truist (Buy) and Wells Fargo (Overweight) both cut their price targets in mid-April — Truist to $34, Wells to $32 — while Citi (Neutral) trimmed to $22. Baird sits at the high end with an Outperform and a $55 target, though that target was set back in March when the stock was trading differently. With EQPT now at $24.55, Citi's $22 target implies modest downside, while the three buy-rated targets cluster between $32 and $55. The ORTEX short score has nudged higher all week, reaching 74.6 on May 12 — elevated, reflecting the combined weight of rising short interest and tighter borrow, but not yet at the extreme end of the range. The EV/EBITDA multiple of 3.2x and a P/E near 35x describe a company priced modestly on asset value but carrying a meaningful earnings growth premium for a recent IPO.
Ownership data flags something worth noting. Two of the largest holders — Jabbok Schlacks and William Schlacks, each holding 7.4% of shares — are listed as co-founders, and their positions appear unchanged from January. The single institutional disclosure of note is that Vanguard, T. Rowe Price, and JP Morgan Asset Management are all reported as new holders with fresh Q1 positions, suggesting that index and active buyers were establishing stakes right at or around the IPO. That provides some structural support, though the lock-up calendar for pre-IPO holders remains the largest unknown for medium-term float dynamics.
Post-earnings reactions give short sellers historical reason for caution. The March 2026 earnings event — the company's first as a public company — produced an 8.3% single-day drop and a 16% decline over the following five days. The setup today is different: the stock has already run hard into the print, up 27% on the week, raising the stakes on both sides. The next read on how the market digests the inaugural results therefore centres less on any single quarterly number and more on whether management's commentary on the OWN Program expansion, utilisation rates, and branch cost growth can shift the bear case that has been quietly rebuilding in the background all month.
See the live data behind this article on ORTEX.
Open EQPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
